Revitope Oncology Revitope Oncology is a biotechnology company focused on developing of T cell redirecting biologics. | ![]() Infinity Pharmaceuticals Infinity Pharmaceuticals engages in the discovery and development of medicines for the treatment of cancer and related conditions. | ![]() Heidelberg Pharma Heidelberg Pharma is a drug development company that provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries. | ||
Founding Date | Founding Date 2016 | Founding Date 2000 | Founding Date 1994 | Founding Date 1997 |
Type | Type Private | Type Public | Type Public | Type Public |
Tags | ||||
Locations | Locations Cambridge, US HQ | Locations Cambridge, US HQ | Locations Alameda, US HQ | Locations Ladenburg, DE HQ Ladenburg, DE |
Employees | Employees 717% increase | Employees 25 | Employees 1,14712% decrease | Employees 60 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 726.1 k | Valuation ($) 8.2 b | Valuation ($) 158.3 m |
Financial | ||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $2.6m (FY, 2022) | Revenue (est.) $2.3b (FY, 2025) | Revenue (est.) €1.5m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $83.7m (FY, 2025) | Cost of goods (€2.5m) (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $2.2b (FY, 2025) | Gross profit €6.3m (FY, 2025) |
Net income | Net income N/A | Net income ($44.4m) (FY, 2022) | Net income $782.6m (FY, 2025) | Net income (€42.3m) (FY, 2025) |

Infinity Pharmaceuticals engages in the discovery and development of medicines for the treatment of cancer and related conditions.
View company
Exelixis is an oncology company that develops cancer treatments.
View company
Heidelberg Pharma is a drug development company that provides pre-clinical drug discovery and development services for the development of anti-cancer and anti-inflammatory drugs to pharmaceutical and biotechnology industries.
View company